Tempus AI Stock News

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to provide testing and contract research organization (CRO) services in support of the agency's...

Short interest is a powerful market force that can not only cap gains but drive share prices lower, but not always. Sometimes, even the short sellers get things wrong.

What a difference a week can make on the stock market. Next-generation healthcare tech company Tempus AI's (TEM 1.56%) stock was doing quite well, thank you very much, over the past few days, in contrast to the preceding five-day trading stretch.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution.

Artificial intelligence (AI) is transforming the world in much the same way as the adoption of the internet did 30 years ago. This is about more than just search; AI is changing the way many industries handle administrative tasks.

There's no doubt about it. The technology sector has been a great place to invest for decades.

Prior to the start of this week, Tempus AI (TEM -2.55%) stock had locked in a 161% gain since the start of the year -- an impressive performance for the healthcare company that's pioneering artificial intelligence (AI) solutions for improving patient outcomes. This week, however, Main Street noted a well-known investor's decision to trim her position in Tempus AI stock, and the stock plunged.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device. xR IVD will be offered as a life sciences tool to support drug development programs. RNA sequencing captur...